FMC Corporation Q2 2026 Earnings Recap

The stock gained 7.0% on the news that first quarter results surpassed expectations, driven by better-than-anticipated sales volume, foreign exchange benefits, and cost controls that fueled EBITDA upside.

Key Takeaways

• First quarter sales of $762 million came in $12 million above the midpoint of guidance, despite a 4% year-over-year decline.
• Volume increased 2% with a 5% positive foreign exchange impact; FMC-branded sales grew 6% on a like-for-like basis, led by EMEA and North America herbicides and Cyazypyr.
• Price declined 6%, largely due to diamide partner volumes and Rynaxypyr price repositioning as part of the post-patent strategy.
• Adjusted EBITDA reached $72 million, exceeding guidance by $17 million, benefiting from favorable FX, volume, and cost improvements.
• Adjusted loss per share was $0.23, $0.15 better than the midpoint of guidance, reflecting improved operational efficiency and FX gains.